Matches in SemOpenAlex for { <https://semopenalex.org/work/W1674191906> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W1674191906 endingPage "94" @default.
- W1674191906 startingPage "5187" @default.
- W1674191906 abstract "The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and preliminary activity of BMS-188797 administered weekly.Patients with advanced malignancies were treated with escalating doses of BMS-188797 on a weekly schedule as a 1-h i.v. infusion. Plasma sampling was performed to characterize the pharmacokinetics of BMS-188797.Eighteen patients with advanced malignancies were enrolled at three dose levels ranging from 35 to 65 mg/m(2). The number of patients evaluated at each dose level was as follows: 35 mg/m(2) (n = 3); 50 mg/m(2) (n = 9); and 65 mg/m(2) (n = 6). At 65 mg/m(2), three of six patients had a DLT (one had grade 4 neutropenia lasting >7 days, and two had grade 3 diarrhea). Expansion of the 50-mg/m(2) dose cohort to nine patients established this dose as the MTD, with one patient experiencing a DLT (grade 4 neutropenia with fever). Two partial responses were observed (lung cancer, 7+ months; ovarian cancer, 6+ months durations), as well as two minor responses (esophageal cancer, 5 months; ovarian cancer, 5 months). Both patients with partial responses had been clinically resistant to paclitaxel. Plasma pharmacokinetic mean values of maximum concentration (C(max)) and area under the curve (AUC(0-48)) increased in a dose-dependent manner within the range of doses used in this study, and in three of four patients, the DLTs correlated with AUC.The MTD and the recommended Phase II dose of weekly BMS-188797 is 50 mg/m(2). The drug demonstrates antitumor activity in taxane-refractory solid tumors and is now being evaluated in combination with carboplatin." @default.
- W1674191906 created "2016-06-24" @default.
- W1674191906 creator A5016706552 @default.
- W1674191906 creator A5019649110 @default.
- W1674191906 creator A5026865203 @default.
- W1674191906 creator A5036188351 @default.
- W1674191906 creator A5041301470 @default.
- W1674191906 creator A5048410242 @default.
- W1674191906 creator A5060314041 @default.
- W1674191906 creator A5071951379 @default.
- W1674191906 date "2003-11-01" @default.
- W1674191906 modified "2023-10-18" @default.
- W1674191906 title "Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies." @default.
- W1674191906 cites W188630526 @default.
- W1674191906 cites W1892438397 @default.
- W1674191906 cites W1929450387 @default.
- W1674191906 cites W1946819517 @default.
- W1674191906 cites W1980896309 @default.
- W1674191906 cites W2002641744 @default.
- W1674191906 cites W2037605675 @default.
- W1674191906 cites W2071496368 @default.
- W1674191906 cites W2093659095 @default.
- W1674191906 cites W2114612380 @default.
- W1674191906 cites W2283078733 @default.
- W1674191906 cites W2335667890 @default.
- W1674191906 cites W2491374885 @default.
- W1674191906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14613998" @default.
- W1674191906 hasPublicationYear "2003" @default.
- W1674191906 type Work @default.
- W1674191906 sameAs 1674191906 @default.
- W1674191906 citedByCount "6" @default.
- W1674191906 countsByYear W16741919062012 @default.
- W1674191906 crossrefType "journal-article" @default.
- W1674191906 hasAuthorship W1674191906A5016706552 @default.
- W1674191906 hasAuthorship W1674191906A5019649110 @default.
- W1674191906 hasAuthorship W1674191906A5026865203 @default.
- W1674191906 hasAuthorship W1674191906A5036188351 @default.
- W1674191906 hasAuthorship W1674191906A5041301470 @default.
- W1674191906 hasAuthorship W1674191906A5048410242 @default.
- W1674191906 hasAuthorship W1674191906A5060314041 @default.
- W1674191906 hasAuthorship W1674191906A5071951379 @default.
- W1674191906 hasConcept C112705442 @default.
- W1674191906 hasConcept C121608353 @default.
- W1674191906 hasConcept C126322002 @default.
- W1674191906 hasConcept C2776256026 @default.
- W1674191906 hasConcept C2776694085 @default.
- W1674191906 hasConcept C2777063308 @default.
- W1674191906 hasConcept C2777511904 @default.
- W1674191906 hasConcept C2780427987 @default.
- W1674191906 hasConcept C530470458 @default.
- W1674191906 hasConcept C71924100 @default.
- W1674191906 hasConcept C76318530 @default.
- W1674191906 hasConcept C90924648 @default.
- W1674191906 hasConceptScore W1674191906C112705442 @default.
- W1674191906 hasConceptScore W1674191906C121608353 @default.
- W1674191906 hasConceptScore W1674191906C126322002 @default.
- W1674191906 hasConceptScore W1674191906C2776256026 @default.
- W1674191906 hasConceptScore W1674191906C2776694085 @default.
- W1674191906 hasConceptScore W1674191906C2777063308 @default.
- W1674191906 hasConceptScore W1674191906C2777511904 @default.
- W1674191906 hasConceptScore W1674191906C2780427987 @default.
- W1674191906 hasConceptScore W1674191906C530470458 @default.
- W1674191906 hasConceptScore W1674191906C71924100 @default.
- W1674191906 hasConceptScore W1674191906C76318530 @default.
- W1674191906 hasConceptScore W1674191906C90924648 @default.
- W1674191906 hasIssue "14" @default.
- W1674191906 hasLocation W16741919061 @default.
- W1674191906 hasOpenAccess W1674191906 @default.
- W1674191906 hasPrimaryLocation W16741919061 @default.
- W1674191906 hasRelatedWork W1674191906 @default.
- W1674191906 hasRelatedWork W1922777011 @default.
- W1674191906 hasRelatedWork W1997680157 @default.
- W1674191906 hasRelatedWork W2034224602 @default.
- W1674191906 hasRelatedWork W2048937876 @default.
- W1674191906 hasRelatedWork W2057396279 @default.
- W1674191906 hasRelatedWork W2098766256 @default.
- W1674191906 hasRelatedWork W2125904513 @default.
- W1674191906 hasRelatedWork W2141395077 @default.
- W1674191906 hasRelatedWork W3123878640 @default.
- W1674191906 hasVolume "9" @default.
- W1674191906 isParatext "false" @default.
- W1674191906 isRetracted "false" @default.
- W1674191906 magId "1674191906" @default.
- W1674191906 workType "article" @default.